Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain.
about
A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophreniaThe chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR functionModulatory effects of α7 nAChRs on the immune system and its relevance for CNS disordersThe human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and functionCholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activitySpatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouseSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergencenAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptorMuscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaOlfactory discrimination varies in mice with different levels of α7-nicotinic acetylcholine receptor expressionCognitive effects of nicotine: genetic moderators.Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measuresSmoking, Genetics and Schizophrenia: Evidence for Self Medication.Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.The 5-choice continuous performance test: evidence for a translational test of vigilance for mice.Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers.Theranostic Biomarkers for SchizophreniaStudies on the hippocampal formation: From basic development to clinical applications: Studies on schizophreniaNeuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Activation of the Alpha-7 Nicotinic Acetylcholine ReceptorFluorine--a current literature review. An NRC and ATSDR based review of safety standards for exposure to fluorine and fluorides.Meta-analyses of 10 polymorphisms associated with the risk of schizophrenia.Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study.Dietary choline supplementation improves behavioral, histological, and neurochemical outcomes in a rat model of traumatic brain injury.Genetic Association Study of the Alpha 7 Nicotinic Receptor (CHRNA7) with the Development of Schizophrenia and Bipolar Disorder in Korean Population.Design, synthesis, and pharmacological characterization of novel spirocyclic quinuclidinyl-Δ2-isoxazoline derivatives as potent and selective agonists of α7 nicotinic acetylcholine receptors.α7-Nicotinic acetylcholine receptor: role in early odor learning preference in miceThe duplicated α7 subunits assemble and form functional nicotinic receptors with the full-length α7.Function of partially duplicated human α77 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response.α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.Role of the central cholinergic system in the therapeutics of schizophrenia.Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain.Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).
P2860
Q21203917-0764FE38-A16E-482F-B4CD-092069E31612Q24308763-7C56CAAD-BD46-4025-B195-F519808974A5Q26765419-A96113A2-DDA5-4495-8361-9913ECA36AFEQ26821785-E3296660-F142-4A67-BB45-2471FC7A8D0FQ26991451-039B9F60-1EDD-410F-9B2E-58BA2C8A77E9Q28573052-B9B6E2A6-7559-49D6-9C20-E05F8B9A7FA5Q29618819-50B6CBDF-FF8F-470A-8906-58A7E6CD1262Q30362464-CDF3D9BF-F54E-485F-B612-02D27DE62DAAQ30366697-70469923-CB7F-4A66-9E95-29E34C0B92B1Q30396291-DA80421C-5CA5-4E00-A672-AA24F7E6DABAQ30407039-D79BFB5C-9B84-4FD4-A773-25D93D9827F1Q30428422-95BFA1A6-F71A-4915-B478-6D27C1923C5DQ30453198-4333A265-17EA-47E6-866F-1FE96D73F4BFQ30459624-342EAE40-CC85-483F-AEE1-2FC28B77F8BCQ30473395-361E031A-96A5-4CF9-BF7B-30DFCFDDC1C4Q30474904-D38557A8-7827-4D8D-95E0-C57E3CDBFB03Q30491325-170D941F-2BDC-404E-8912-F074DE4B1DDBQ30491841-60010B9C-23D3-4CC9-98C1-765740E0E26CQ30493072-B427D0A5-D36D-408C-984F-1D1AB1331F0AQ33401264-E6DCD711-F4DD-4862-9B73-03114348CFA5Q33598688-10584BB4-1261-479E-B6CA-2C643EACF812Q33624412-2916E9CF-AC60-43AB-99D3-838ED7623C5BQ33691327-1E64763A-C32C-4BA6-9DB0-6B230C61F037Q33740560-BC3F9766-5BB8-470D-BFE2-B75D8148A732Q33810554-82953793-F083-4EBE-8A13-889C17D61201Q33932502-9D1DEC98-DFF2-4A61-9D7A-D54E1D1B83F5Q33933877-4B281026-6434-44C3-8A8F-978080F998B8Q34160594-6938FEE0-8E65-415D-9175-8412CB87077AQ34165058-7EE28363-D49A-474B-832A-34D4B0D91857Q34167942-B7247B00-2090-4257-8FBE-5FF220750BA5Q34238932-249D2EE0-63E5-423D-A80A-D5BC9CA676A0Q34249085-B32B5634-FBFF-4A2A-B402-06AF06A9DA79Q34452664-11BE69BF-9616-4935-BB6E-E35EF96E4A24Q34501147-67C0A88F-6B59-4D4D-AF21-A6B68F619B32Q34531316-C9A02D92-E9A3-4A07-826E-199DB6351CB5Q34608625-A2404778-E66E-4740-85E0-67DDC3D7A737Q34926526-91F439CF-4CCF-4F55-9A72-5D8846A46633Q35048154-147AF3CE-4072-44EC-B4F5-0C8710B483FEQ35389369-C3A3E2DE-3CE2-4AFB-8499-2E284FF0E740Q35604900-4ED59594-DEF7-45A8-BDD2-B4C84F1C8255
P2860
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Decreased protein level of nic ...... rtex from schizophrenic brain.
@en
type
label
Decreased protein level of nic ...... rtex from schizophrenic brain.
@en
prefLabel
Decreased protein level of nic ...... rtex from schizophrenic brain.
@en
P1433
P1476
Decreased protein level of nic ...... rtex from schizophrenic brain.
@en
P304
P356
10.1097/00001756-199906030-00028
P577
1999-06-01T00:00:00Z